Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Chubb
Novartis
Farmers Insurance
Cipla
Fish and Richardson
Baxter
QuintilesIMS
Daiichi Sankyo
Express Scripts

Generated: October 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,481,565

« Back to Dashboard

Which drugs does patent 8,481,565 protect, and when does it expire?


Patent 8,481,565 protects ARICEPT and is included in one NDA. There has been one Paragraph IV challenge on Aricept.

This patent has thirty-six patent family members in fifteen countries.

Summary for Patent: 8,481,565

Title:Method for stabilizing anti-dementia drug
Abstract: The present invention provides a method for stabilizing an anti-dementia drug in a pharmaceutical composition containing the anti-dementia drug and a high molecular weight basic substance by adding a high molecular weight acidic substance to said pharmaceutical composition. Further, the present invention provides a pharmaceutical composition containing an anti-dementia drug and a high molecular basic substance in which a high molecular weight acidic substance is contained for stabilizing the anti-dementia drug. Furthermore, the present invention provides a method for manufacturing a pharmaceutical composition which comprises steps wherein a solution or suspension containing a high molecular weight acidic substance is added to a mixture of an anti-dementia drug and a high molecular weight basic substance for the sake of stabilizing the anti-dementia drug.
Inventor(s): Ueki; Yosuke (Kakamigahara, JP), Suzuki; Yasuyuki (Kakamigahara, JP), Fujioka; Satoshi (Kakamigahara, JP)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:11/793,722
Patent Claim Types:
see list of patent claims
Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eisai Inc
ARICEPT
donepezil hydrochloride
TABLET;ORAL022568-001Jul 23, 2010ABRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,481,565

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2004-376770Dec 27, 2004
Japan2005-041492Feb 18, 2005
PCT Information
PCT FiledDecember 27, 2005PCT Application Number:PCT/JP2005/024254
PCT Publication Date:July 06, 2006PCT Publication Number: WO2006/070930

Non-Orange Book Patents for Patent: 8,481,565

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,507,527Method for stabilizing anti-dementia drug► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,481,565

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2005320547► Subscribe
Australia2005320609► Subscribe
BrazilPI0518396► Subscribe
BrazilPI0519407► Subscribe
Canada2592102► Subscribe
Canada2592605► Subscribe
China101090737► Subscribe
China101090738► Subscribe
China103550190► Subscribe
European Patent Office1830886► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Boehringer Ingelheim
Merck
Julphar
Fish and Richardson
Chinese Patent Office
Mallinckrodt
McKinsey
Accenture
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot